secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2025-05-27T23:59:59+00:00
Accession:  0001213900-25-047805
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada shareholders elect director, ratify auditor, approve 2M share increase to 2021 equity plan
--------------------------------------------------------------------------------

- Annual meeting held May 23, 2025; 53.6% quorum attained.
- John Glasspool elected Class I director (36-month term) with 7.14M for, 2.60M withheld.
- Ratification of CBIZ CPAs as auditor for FY2025 approved: 16.44M for, 0.86M against.
- Amendment to 2021 Plan approved: share pool increased by 2,000,000 to 9,900,000 total.
- Continuing Class II directors: Charles Casamento and Sergio Traversa; Class III: John Glasspool and Paul Kelly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025047805/0001213900-25-047805-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025047805/ea0243544-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-047805

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer